F
FibroGen, Inc.
FGENHealth Care· San Francisco, California, United States
LAYOFFS TRACKED
2
LAST EVENT
Aug 2, 2024
MARKET CAP
—
EMPLOYEES
520
FibroGen, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapies to treat serious unmet medical needs, with a focus on anemia, fibrosis and cancer. Its lead marketed product is roxadustat (approved in some markets for anemia due to chronic kidney disease), and it maintains research programs in fibrotic disease and oncology.
Layoff history
EMPLOYEES AFFECTED PER QUARTER · HOVER FOR DETAILS
104
127
Q3 '23Q1 '24Q1 '25Q1 '26Q3 '26
Layoff timeline
2 EVENTSStories from here
No one has shared a story from FibroGen yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →Get alerts for FibroGen
We'll email you the moment a new layoff is reported here.